The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Antiarrhythmic drugs (AADs) are often used after ablation for atrial fibrillation (AF); the drugs employed vary, but most common are the drugs that were unsuccessful prior to ablation since it ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.

Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...

but maintain ablation success rates, in patients with persistent atrial fibrillation. The findings are promising; however, important limitations and concerns must be overcome before use of this ...

Johnson & Johnson MedTech (NYSE: JNJ) announced that it received CE mark approval for its dual-energy ThermoCool SmartTouch ...

The Ordensklinikum Linz Elisabethinen is one of the first centers worldwide and the first center in Austria to use a new ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

The following is a summary of “Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes,” published in the ...

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for the treatment of cardiac ...